{"id":"https://openalex.org/W2980249212","doi":"https://doi.org/10.1182/blood.v114.22.1063.1063","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody\u00ae ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.","display_name":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody\u00ae ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2980249212","doi":"https://doi.org/10.1182/blood.v114.22.1063.1063","mag":"2980249212"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.1063.1063","doi":"https://doi.org/10.1182/blood.v114.22.1063.1063","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.1063.1063","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006346623","display_name":"Khalid Abd\u2010Elaziz","orcid":"https://orcid.org/0000-0002-0964-4940","observed_orcids":["https://orcid.org/0000-0002-0964-4940"]},"institutions":[{"id":"https://openalex.org/I4210165647","display_name":"Xendo (Netherlands)","ror":"https://ror.org/05dw0jd27","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210165647"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Khalid Abd-Elaziz","raw_affiliation_strings":["Xendo Drug Development, Groningen, Netherlands,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xendo Drug Development, Groningen, Netherlands,","institution_ids":["https://openalex.org/I4210165647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080634466","display_name":"Pieter Willem Kamphuisen","orcid":"https://orcid.org/0000-0002-6263-0177","observed_orcids":["https://orcid.org/0000-0002-6263-0177"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Pieter W. Kamphuisen","raw_affiliation_strings":["Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands,","institution_ids":["https://openalex.org/I2802928900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021204277","display_name":"Christophe Lyssens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Christophe Lyssens","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043891530","display_name":"Mariska Reuvers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165647","display_name":"Xendo (Netherlands)","ror":"https://ror.org/05dw0jd27","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210165647"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Mariska Reuvers","raw_affiliation_strings":["Xendo Drug Development, Groningen, Netherlands,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xendo Drug Development, Groningen, Netherlands,","institution_ids":["https://openalex.org/I4210165647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073968965","display_name":"Izaak den Daas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165647","display_name":"Xendo (Netherlands)","ror":"https://ror.org/05dw0jd27","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210165647"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Izaak den Daas","raw_affiliation_strings":["Xendo Drug Development, Groningen, Netherlands,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xendo Drug Development, Groningen, Netherlands,","institution_ids":["https://openalex.org/I4210165647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008136643","display_name":"Femke Van Bockstaele","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Femke Van Bockstaele","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051500520","display_name":"Kristof Vercruysse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Kristof Vercruysse","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056713280","display_name":"Hans Ulrichts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Hans Ulrichts","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111614201","display_name":"Judith Baumeister","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Judith Baumeister","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046374494","display_name":"Patricia Crabbe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Patricia Crabbe","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073486104","display_name":"Veerle Compernolle","orcid":"https://orcid.org/0000-0001-5477-9804","observed_orcids":["https://orcid.org/0000-0001-5477-9804"]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Veerle Compernolle","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068091975","display_name":"Josefin-Beate Holz","orcid":"https://orcid.org/0000-0003-4618-408X","observed_orcids":["https://orcid.org/0000-0003-4618-408X"]},"institutions":[{"id":"https://openalex.org/I124674891","display_name":"Ablynx (Belgium)","ror":"https://ror.org/05s030550","country_code":"BE","type":"company","lineage":["https://openalex.org/I124674891"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Josefin-Beate Holz","raw_affiliation_strings":["Ablynx NV, Zwijnaarde, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ablynx NV, Zwijnaarde, Belgium","institution_ids":["https://openalex.org/I124674891"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5006346623","https://openalex.org/A5008136643","https://openalex.org/A5021204277","https://openalex.org/A5043891530","https://openalex.org/A5046374494","https://openalex.org/A5051500520","https://openalex.org/A5056713280","https://openalex.org/A5068091975","https://openalex.org/A5073486104","https://openalex.org/A5073968965","https://openalex.org/A5080634466","https://openalex.org/A5111614201"],"corresponding_institution_ids":["https://openalex.org/I124674891","https://openalex.org/I2802928900","https://openalex.org/I4210165647"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4134,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.65765671,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"114","issue":"22","first_page":"1063","last_page":"1063"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.8521000146865845,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.8521000146865845,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.13729999959468842,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12352","display_name":"Heparin-Induced Thrombocytopenia and Thrombosis","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nanobodies","display_name":"nanobodies","score":0.6890000104904175},{"id":"https://openalex.org/keywords/von-willebrand-factor","display_name":"von Willebrand factor","score":0.9750000238418579},{"id":"https://openalex.org/keywords/a1-domain","display_name":"A1 domain","score":0.7630000114440918},{"id":"https://openalex.org/keywords/thrombotic-thrombocytopenic-purpura","display_name":"thrombotic thrombocytopenic purpura","score":0.9909999966621399},{"id":"https://openalex.org/keywords/platelet-inhibition","display_name":"platelet aggregation inhibition","score":0.7419999837875366},{"id":"https://openalex.org/keywords/ristocetin-cofactor-activity","display_name":"ristocetin cofactor activity","score":0.8769999742507935},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8159999847412109},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9929999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6869999766349792},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6669999957084656},{"id":"https://openalex.org/keywords/hemorrhage","display_name":"hemorrhage","score":0.4020000100135803},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9089999794960022},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6589999794960022},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.7789999842643738},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8004951477050781},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6607540845870972},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6299962401390076},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6119478344917297},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5462105870246887},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5413131713867188},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.516316831111908},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5037347674369812},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.48836132884025574},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4121035933494568},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3716297745704651},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.27493369579315186},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1158076822757721},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1182/blood.v114.22.1063.1063","doi":"https://doi.org/10.1182/blood.v114.22.1063.1063","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.1063.1063","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmh:oai:pure.rug.nl:openaire_cris_publications/4fcd5d57-e14e-4b1a-a5f1-20e70c952b1b","doi":null,"is_oa":false,"landing_page_url":"https://research.rug.nl/en/publications/4fcd5d57-e14e-4b1a-a5f1-20e70c952b1b","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Abd-Elaziz , K 2009 , ' Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody\u00ae ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers. ' , Blood .","raw_type":"article"},{"id":"pmh:oai:pure.rug.nl:openaire_cris_publications/90cee51d-e006-44f8-af79-b13f2273a959","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11370/90cee51d-e006-44f8-af79-b13f2273a959","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Abd-Elaziz, K, Kamphuisen, P W, Lyssens, C, Reuvers, M, Den Daas, I, Van Bockstaele, F, Vercruysse, K, Ulrichts, H, Baumeister, J, Crabbe, P, Compernolle, V & Holz, J-B 2009, 'Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-VWF nanobody\u00ae ALX-0681 after single and multiple subcutaneous administrations to healthy volunteers', Blood, vol. 114, no. 22.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:rug:oai:pure.rug.nl:publications/90cee51d-e006-44f8-af79-b13f2273a959","doi":null,"is_oa":false,"landing_page_url":"https://research.rug.nl/en/publications/90cee51d-e006-44f8-af79-b13f2273a959","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Blood, 114(22). AMER SOC HEMATOLOGY","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2068472697","https://openalex.org/W7098974780","https://openalex.org/W4247752383","https://openalex.org/W2092900379","https://openalex.org/W55047121","https://openalex.org/W2980244494","https://openalex.org/W1984311552","https://openalex.org/W2009524685","https://openalex.org/W2116433463","https://openalex.org/W2328719089"],"abstract_inverted_index":{"Abstract":[0,1],"1063":[2],"Poster":[3],"Board":[4],"I-85":[5],"ALX-0681":[6,37,108,136,151,161,251,500,523,569,753,821,846,866],"is":[7],"a":[8,49,298,496,511,573,830,852],"humanized":[9],"bivalent":[10],"Nanobody\u00ae,":[11],"that":[12],"binds":[13],"to":[14,78,101,124,535,745,758,859],"the":[15,60,80,91,103,126,239,304,557,809,841,861,868],"A1":[16],"domain":[17],"of":[18,35,69,97,107,128,135,156,230,248,271,274,288,293,300,310,316,532,541,568,582,598,604,780,792,802,817,820,832,837,843,865],"von":[19],"Willebrand":[20],"factor":[21],"(vWF)":[22],"and":[23,51,90,95,132,221,227,254,276,565,577,591,764,863],"hence":[24],"blocks":[25],"its":[26,33],"interaction":[27],"with":[28,150,279,318,522,538,606],"platelet":[29,57,249,795],"receptor":[30],"GPIb-IX-V.":[31],"Given":[32],"mode":[34],"action,":[36],"could":[38],"provide":[39],"an":[40,539,826],"alternative":[41],"treatment":[42,281,812],"option":[43],"for":[44,146,297,756,829],"thrombotic":[45],"thrombocytopenic":[46],"purpura":[47],"(TTP),":[48],"rare":[50],"life-threatening":[52],"condition":[53],"characterized":[54],"by":[55,63,237,510],"systemic":[56],"aggregation":[58,796],"in":[59,74,99,109,119,499,575,768,825,856,867],"microcirculation":[61],"mediated":[62,246,794],"activated":[64],"vWF":[65,245,576,615,793],"multimers.":[66],"The":[67,232,269,786],"goal":[68],"this":[70,120,844],"Phase":[71,92,147,853],"I":[72,148],"trial":[73,149],"healthy":[75,115],"volunteers":[76,116],"was":[77,235,252,548,761,806],"determine":[79],"maximum":[81],"tolerated":[82,256,763],"dose":[83,88,166,198,259,339,430,558,628,695],"(MTD)":[84],"or":[85,527,778],"biologically":[86],"effective":[87],"(BED)":[89],"II":[93,854],"dosing":[94],"scheduling":[96],"ALX-0681,":[98],"order":[100],"support":[102],"further":[104],"clinical":[105],"development":[106,847],"TTP":[110,857],"patients.":[111],"In":[112,751],"total,":[113],"36":[114],"were":[117,287,295,588,784],"included":[118,213],"randomized,":[121],"placebo-controlled":[122],"study":[123,855],"evaluate":[125],"safety":[127,214,312,862],"single":[129,798],"ascending":[130],"doses":[131,134,158],"multiple":[133],"administered":[137,754],"subcutaneously":[138],"(s.c.)":[139],"(Table":[140,261,560],"1).":[141],"Table":[142,307,595],"1":[143,168,170,172,176,178,182,184,188,190,194,196,347,351,362,381,398,403,411,437,441,454,458,485,647,649],"Dosing":[144],"schedule":[145],"Cohort":[152,167,173,179,185,191,199,205],"Dose":[153,320,608],"(mg)":[154],"Number":[155],"daily":[157,799,815],"Subjects":[159,162,322,610,621],"receiving":[160,163],"placebo":[164],"Single":[165,338,627],"2":[169,174,204,210,308,340,343,358,449,450,480,481,629,632,643,671,710,733,810],"3":[171,177,180,183,189,195,342,357,372,373,387,388,402,417,445,596,631,636,642,653,654,658,660,664,665,675,676,680,682,706],"4":[175,186,355,474,640],"8":[181,370,525,651],"16":[187,385,662],"5":[192,416,439,470,472,476,685,704,727,729],"10":[193,201,207,400,431,462,673,696,719,803],"Multiple":[197,429,694,814],"6":[200,203,209,434,435,465,466,699,700,722,723],"7":[202,206],"14":[208,759],"Study":[211],"endpoints":[212],"(dose":[215],"limiting":[216],"toxicities,":[217],"adverse":[218],"events":[219,286,587],"(AEs)":[220],"immunogenicity),":[222],"pharmacokinetics":[223],"(PK),":[224],"pharmacodynamics":[225],"(PD)":[226],"pharmacological":[228],"efficacy":[229,864],"ALX-0681.":[231],"latter":[233],"endpoint":[234],"addressed":[236],"measuring":[238],"ristocetin":[240],"cofactor":[241],"(RICO)":[242],"biomarker,":[243],"reflecting":[244],"inhibition":[247,531,547,791],"aggregation.":[250],"safe":[253],"well":[255,762],"at":[257,328,332,524],"all":[258,284,589],"levels":[260,579],"2).":[262],"One":[263],"unrelated":[264],"SAE":[265,325],"(meniscus":[266],"lesion)":[267],"occurred.":[268],"number":[270],"observed":[272,296],"signs":[273,292,779],"bleeding":[275,783],"bruises":[277],"increased":[278],"increasing":[280],"duration.":[282],"However,":[283],"these":[285],"mild":[289],"intensity.":[290],"No":[291,773],"immunogenicity":[294],"minimum":[299,831],"45":[301,833],"days":[302,760,834],"after":[303],"last":[305],"injection.":[306],"Summary":[309,597],"main":[311,599],"results":[313,601,842],"(number":[314,602],"(%)":[315,603,622],"subjects":[317,520,571,605],"event)":[319,607],"level":[321,559,609],"(n)":[323,611],"AE":[324],"Bleeding":[326],"Hematoma":[327,331],"injection":[329],"site":[330,335],"blood":[333],"sampling":[334],"Other":[336],"hematoma":[337],"mg":[341,356,371,386,401,432,463,526,630,641,652,663,674,697,720],"(67)":[344,359,475,633,644,672],"0":[345,349,353,360,364,366,368,375,377,379,383,390,392,394,396,405,407,409,413,419,421,423,425,427,443,452,456,460,468,483,487,489,491,638,669,686,690,692,711,715,717,734,738,740],"(0)":[346,350,354,361,365,367,369,376,378,380,384,391,393,395,397,406,408,410,414,420,422,424,426,428,444,453,457,461,469,484,488,490,492,639,670,687,691,693,712,716,718,735,739,741],"(33)":[348,352,363,382,399,404,412,648,650],"(100)":[374,389,436,451,467,482,637,655,659,661,666,677,681,683,701,724],"Placebo":[415,447,478,684,708,731],"(60)":[418],"(7d)":[433,448,698,709],"(17)":[438,442],"(83)":[440,471,473,477,705,728,730],"(50)":[446,455,459,486,707],"(14d)":[464,479,721,732],"PK":[493],"analysis":[494],"showed":[495,529],"rapid":[497],"increase":[498],"plasma":[501],"concentration":[502],"(tmax":[503],"=":[504,516],"4-10":[505],"h":[506,543,552],"post":[507,544,553],"dose),":[508],"followed":[509],"slow":[512],"elimination":[513],"phase":[514],"(t1/2":[515],"10-78":[517],"h).":[518],"All":[519],"dosed":[521],"higher":[528],"complete":[530,790],"RICO":[533,612],"activity":[534],"<":[536,613,616,619],"20%":[537,614],"onset":[540],"1-6":[542],"dose.":[545],"This":[546],"maintained":[549,807],"until":[550],"12-360":[551],"dose,":[554],"depending":[555],"on":[556,840],"3).":[561],"Overall,":[562],"20":[563],"(74%)":[564],"17":[566],"(63%)":[567],"treated":[570],"experienced":[572],"drop":[574],"FVIII":[578,618],"below":[580],"50%":[581,617,620],"pre-dose":[583],"levels,":[584],"respectively.":[585],"These":[586],"transient":[590],"not":[592,749,766,823],"clinically":[593,770,781],"significant.":[594],"PD":[600,787],"Start":[623],"(h)*":[624,626],"Stop":[625],"2-4":[634,656,702,725],"12-18":[635],"4-6":[645],"18-36":[646],"18-48":[657],"1-4":[667],"48":[668],"2-6":[678],"24-36":[679],"NA":[688,689,713,714,736,737],"168-192":[703],"336-360":[726],"*":[742],"Time":[743],"relative":[744],"first":[746],"administration":[747,816],"NA:":[748],"applicable":[750],"conclusion,":[752],"s.c.":[755,800,818],"up":[757],"did":[765,822],"result":[767,824],"any":[769],"significant":[771],"AEs.":[772],"local":[774,776],"reactions,":[775],"intolerances":[777],"relevant":[782],"reported.":[785],"marker":[788],"indicated":[789],"following":[797,835],"injections":[801,819],"mg,":[804],"which":[805],"over":[808],"weeks":[811],"period.":[813],"immunogenic":[827],"reaction":[828],"completion":[836],"treatment.":[838],"Based":[839],"study,":[845],"will":[848],"be":[849],"advanced":[850],"into":[851],"patients":[858],"investigate":[860],"target":[869],"patient":[870],"population.":[871],"Disclosures:":[872],"Abd-Elaziz:":[873],"Ablynx":[874],"NV:":[875,878,881,884,888,892,895,898,901,904,907,910],"Consultancy.":[876,879,885,889],"Kamphuisen:Ablynx":[877],"Lyssens:Ablynx":[880],"Employment.":[882,893,896,899,902,905,908,911],"Reuvers:Ablynx":[883],"den":[886],"Daas:Ablynx":[887],"Van":[890],"Bockstaele:Ablynx":[891],"Vercruysse:Ablynx":[894],"Ulrichts:Ablynx":[897],"Baumeister:Ablynx":[900],"Crabbe:Ablynx":[903],"Compernolle:Ablynx":[906],"Holz:Ablynx":[909]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-10-18T00:00:00"}